News

2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007
Resverlogix Closes Equity Offering
Resverlogix Announces Full Enrollment of SUSTAIN, a Phase 2b Clinical Trial Targeting High-Risk Cardiovascular Disease Patients
Resverlogix Announces $17.5 million Equity Offering
Resverlogix Announces the Issuing of Patent Covering RVX-208
Resverlogix Commences Dosing in ASSURE a Phase 2b IVUS Clinical Trial Targeting High-Risk Cardiovascular Disease Patients
Resverlogix Expands Phase 2b Program with the Commencement of Dosing in SUSTAIN
Resverlogix Activates Study Sites in ASSURE Phase 2b IVUS Trial for Atherosclerotic Plaque Regression
Resverlogix Presents Two Abstracts on Analysis of the Phase 2 ASSERT Clinical Trial at The ESC Congress 2011
Resverlogix Presents New Findings on RVX-208 at European Atherosclerosis Society
Resverlogix Announces New Data on Autoimmune Program featured at World Congress of Inflammation
Resverlogix Announces Dr. H. Bryan Brewer Joins Clinical Steering Committee
Resverlogix Closes Equity Offering
Resverlogix Launches Phase IIb ASSURE Trial for RVX-208 Cholesterol Transport Drug, Safety Data Completed and Filed
Resverlogix to Raise $12.6 Million
Resverlogix Announces Overnight Marketed Equity Offering
Resverlogix ASSERT Trial Data Illustrates Potential for RVX-208 in Alzheimer's Disease